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ABSTRACT: Influenza A virus infection causes a contagious
respiratory illness that poses a threat to human health. However,
there are limited anti-influenza A therapeutics available, which is
further compounded by the emergence of drug resistant viruses.
In this study, Sophora quinolizidine alkaloids were identified as a
new class of anti-influenza A virus agents. Among the tested
Sophora alkaloids, dihydroaloperine exhibited the most potent
activity with an EC50 of 11.2 μM. The potency of the
quinolizidine alkaloids was improved by approximately 5-fold
with chemical modifications on the aloperine molecule. These
compounds were effective against an H1N1 influenza A virus that
was resistant to the two antiflu drugs oseltamivir and amantadine.
The identification of the quinolizidine alkaloids as effective and
novel anti-influenza A agents may aid in the development of new therapeutics.
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Influenza A virus (IAV) infection causes a contagiouspandemic respiratory illness that afflicts millions of people
annually. IAV infection could have a lethal consequence, as
evidenced by the 1918 pandemic that caused 30 to 50 million
deaths worldwide.1 The 2009 pandemic swine flu (H1N1)
resulted in the death of an estimated 284,000 people.2 IAV
evolved a promiscuous entry process that uses sialic acid-
containing molecules as receptors to enter cells.3 This allows
the virus to infect cells across various animal species. Avian
influenza viruses, such as H5N1, have circulated in recent years.
Although transmission of avian flu viruses to humans is
inefficient, they are highly pathogenic and may pose a threat if
the viruses acquire the ability for efficient human-to-human
transmission.
The influenza A virus genome contains eight negative-
stranded RNA segments, which encode for 11 viral proteins:
hemagglutinins (HA1; HA2), matrix 1 (M1), matrix 2 (M2),
nucleoprotein (NP), nonstructural protein 1 (NS-1), polymer-
ase acidic protein (PA), polymerase basic proteins (PB1; PB2;
PB1-F2), and neuraminidase (NA).4 Two NA inhibitors,
oseltamivir and zanamivir, are the FDA-approved influenza
antiviral drugs recommended by the US CDC for use against
recently circulating influenza viruses.5 However, emerging drug
resistance and limited effectiveness associated with the NA
inhibitors were reported.6−8 There are other older drugs,
amantadine and rimantadine targeting the M2 ion channel,
approved for treatment and prevention of influenza A.
However, many strains of influenza, such as the 2009 H1N1
influenza virus, are resistant to these two drugs.9 Thus, novel
anti-influenza virus agents are needed to circumvent the
limitations of current drugs.
Quinolizidine alkaloids are known principal constituents in
Sophora species (Fabaceae).10,11 Crude extractions from some
Sophora species containing quinolizidine alkaloids have been
used in traditional Chinese medicinal preparations for
centuries.12 Modern pharmacological studies have shown that
natural products isolated from Sophora plants may protect
against viral infections. For example, some flavonoids isolated
from Sophora f lavescens were found to inhibit the neuramini-
dase of IAV13 or suppress the IAV-induced pro-inflammatory
chemokine production in lung epithelial cells.14 Several
quinolizidine alkaloids including oxymatrine and matrine are
known to have antihepatitis B virus (HBV) activity.15 Thus, to
investigate if the quinolizidine alkaloids can inhibit the IAVs,
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several Sophora alkaloids were tested for their antiviral activity
against IAV. The results of this study indicated that aloperine
(1), a lupine alkaloid found in Sophora species, exhibited the
best anti-IAV activity.16 Aloperine was subsequently used as a
scaffold to derive compounds with improved activity.
Compounds with improved activity were also used in
mechanism of action studies, and the results suggest that
these compounds may inhibit influenza virus infection by
targeting the nucleoprotein of IAV.
Quinolizidine Alkaloids and Their Antiviral Activities.
Pure alkaloids from the Sophora species, including aloperine,
matrine, and oxymatrine, were tested for their activity against a
mouse-adapted influenza virus A/Puerto Rico/8/34 (H1N1)
(PR8). These structurally related alkaloids are called
quinolizidine alkaloids because of their common bicyclic
quinolizidine core. Ring extensions from the quinolizidine
core form subtypes of quinolizidine alkaloids including tricyclic
compounds such as cytisine (5) and tetracyclic compounds
such as (+)- and (−)-sparteine (3 and 4), aloperine (1),
matrine (8), and oxymatrine (7) (Table 1). Among the tested
quinolizidine alkaloids, aloperine protected MDCK cells from
being killed by IAV PR8 at an EC50 of 14.5 μM. Hydrogenation
of aloperine at C16/C17 double bond resulted in a racemic
mixture of dihydroaloperine (2), which was slightly more
potent than aloperine with an EC50 of 11.2 μM. Sparteines also
showed activity against this IAV strain but were approximately
2-fold less potent than aloperine. Matrine, oxymatrine, cytisine,
and methyl cytisine did not inhibit IAV PR8 infection of
MDCK cells. The two antiflu drugs oseltamivir and amantadine
were ineffective against the PR virus, with EC50 greater than 80
μM (Table 1). The compounds listed in Table 1 were not toxic
to MDCK cells at 80 μM. These results suggest that some
quinolizidine alkaloids, such as aloperine and sparteines, can
inhibit IAV infection.
Improved Anti-IAV Potency of Aloperine Derivatives.
Among the active compounds (1−4), sparteines (3 and 4) are
more compact and lack convenient functional groups for
further modifications. In contrast, 1 and 2 possess a secondary
amine that is easy to modify.17 To further increase the anti-IAV
activity, a series of N12 modified aloperine derivatives (9−18)
were synthesized by using a reductive amination method with
suitable aldehydes and sodium triacetoxyborohydride (Scheme
1 and also described in the Supporting Information).
Compounds 9−14 are aloperine derivatives with varied N12
alkyl groups.
The small substitution on N12 increased the potency slightly
as shown by 9 (N-methyl) and 10 (N-ethyl) when compared to
aloperine (NH). Larger N-substitution also resulted in
derivatives with anti-IAV activity as shown by 11−16. Among
them, 16 exhibited the most potent activity against IAV PR8
with an EC50 of 2.4 μM. Hydrogenation of 9 yielded 17 and 18
as a mixture of stereoisomers at C16, which were separated by
HPLC. The cis and trans configurations (C11/C16) of the
decahydroquinonoline subunit in 17 and 18 were determined
based on NMR data included in the Experimental Section
(Supporting Information). Compound 17 was one of the more
potent compounds and had preferred physicochemical proper-
ties among the synthesized derivatives (Mass = 248; Log P =
2.05). Compound 17 inhibited the oseltamivir resistant IAV
PR8 strain with an EC50 of 6.2 μM, which was greater than 2-
fold more potent than 1 with an unmodified N12 amine and
unsaturated C16−C17 bond. Compound 17 was also slightly
more potent than its C16−C17 unsaturated analog 9.
Compound 18, the trans isomer of 17, exhibited comparable
anti-PR8 activity to that of 17 (Table 1).
Aloperine Derivatives Are Effective against the
Oseltamivir Resistant Virus PR8 (H1N1) and Sensitive
Virus VR1679 (H3N2). The predominant current subtypes of
influenza A viruses found in humans are influenza A (H1N1)
and influenza A (H3N2) viruses.18 The PR8 used in this study
is very resistant to oseltamivir, as shown in Table 1. The
aloperine derivative 17 was chosen to test its effects on PR8
and VR1679 due to the simplicity of its structure and synthesis.
Table 1. Anti-IAV Activities of Quinolizidine Alkaloids and
Derivativesa
aA mouse-adapted influenza virus strain A/Puerto Rico/8/1934, PR8,
was used in the assays; EC50 (μM) is the concentration required to
protect the cytocidal effect of the influenza virus PR8 by 50%, which
was presented as mean ± SD from three independent tests; CC50
(μM) is the concentration that reduced the viability of MDCK cells by
50%. bCompounds 1−9 are known compounds. cLog P values were
estimated by using ChemBioDraw Ultra v. 12.0.2 (CambridgeSoft).
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In contrast to PR8, VR1679 was very sensitive to oseltamivir
(Figure 1). Oseltamivir inhibited VR1679 with an EC50 of 0.33
μM, which was at least 200-fold more potent than that against
the H1N1 virus PR8. On the other hand, 17 was approximately
equally potent against the two IAVs. These results suggest that
aloperine derivatives are likely to have a different mechanism of
action from that of oseltamivir.
Compound 17 and Oseltamivir Did Not Share the
Same Mechanism of Action. Oseltamivir is an NA inhibitor
that blocks the release of the influenza virus from infected
cells.19 Therefore, oseltamivir does not prevent IAV entry or
production of viral proteins inside the cells.20 To further
investigate the mechanistic differences in IAV inhibition
between aloperine derivatives and oseltamivir, VR1679 was
used to infect MDCK cells in the presence of the compounds
for 6 h. The viral NP was detected using a confocal microscope
after immunostaining. NP was stained green with FTIC-anti-
NP mAbs, while the cell nuclei were stained blue with
diamidino-2-phenylindole (DAPI).
As expected, oseltamivir at 10 μM did not inhibit NP
production (Figure 2). In fact, VR1679 infected MDCK cells
appeared to accumulate more NP in the presence of oseltamivir
than without the drug. It is likely that inhibition of IAV release
from infected MDCK cells resulted in a backlog of NP within
the cells. NP had been shown to induce apoptosis in cells.21
Thus, oseltamivir might not be effective in protecting the cells
after viral entry. In contrast, compound 17 at 10 μM
completely inhibited the production of VR1679 NP (Figure
2). These results further support the notion that aloperine
derivatives inhibit IAV with a different mechanism of action
from that of oseltamivir.
Compound 17 Inhibited IAV at Multiple Stages of the
Viral Life Cycle. Lack of NP expression in the presence of 17
suggests that the compound inhibits a relatively early step of
the IAV life cycle. To further dissect the drug sensitive phase of
the IAV life cycle, a time of addition assay was performed. The
life cycle of IAV begins with entering into the host cells, which
involves viral HA and M2 proteins.19,20 After entry, the viral
ribonucleoprotein particles (vRNPs) translocate into the
nucleus. The vRNP includes viral RNAs, NP, and polymerases.
Scheme 1. Synthesis of Compounds 9−18a
aReagents and conditions: (a) NaBH(AcO)3, R-CHO, DCE, RT; (b)
N-Boc-2-bromo-ethylamine, K2CO3, MeCN, 110 °C; (c) 55% TFA/
DCM, RT; (d) 2-fluorobenzoic acid, EDC-HCl; DIEA, THF, RT; (e)
2,2-thiophendicarboxylic acid, EDC-HCl; DIEA, THF, RT; (f) H2/
Pd−C, MeOH, RT.
Figure 1. Compound 17 inhibited the oseltamivir resistant IAV PR8.
MDCK cells were infected with PR8 or VR1679 at MOI = 1 in the
presence of 17 or oseltamivir at various concentrations for 2 days.
Protection of MDCK cells from being killed by the virus (%
protection) was calculated with a formula detailed in the Supporting
Information. Each data point in the figure represents mean ± standard
deviation of three independent experiments.
Figure 2. Compound 17 inhibited the accumulation of NP in MDCK
cells. MDCK cells were infected with VR1679 at MOI = 1 in the
presence of 10 μM oseltamivir or compound 17 for 6 h. The cells were
stained with FITC conjugated anti-NP antibodies and DAPI (nuclear
staining). The three images in the top panels were used as controls
with viral infection in the absence of compounds. The confocal images
were acquired using a Nikon TE2000-U laser-scanning confocal
microscope.
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Following transcription and replication of the viral genome,
new vRNPs are exported out of the nucleus. The viral life cycle
is completed after the viruses are assembled and budded at the
plasma membrane of host cells. Oseltamivir targets this very last
step of viral replication cycle by inhibiting NA, which is
required for IAV release from infected cells.
The results of the time of addition assays indicated that both
oseltamivir and 17 were fully active when added before or at 2
h post VR1679 virus infection (Figure 3). Both compounds
partially lost activity when they were added 4 h after viral
infection. The two compounds were ineffective when they were
added 6 h postinfection. These results suggest that compound
17 and oseltamivir can both inhibit IAV at a late stage of the
viral life cycle. This is unexpected because the results of
confocal imaging of NP suggest that compound 17 inhibits IAV
at a relatively early stage of the viral life cycle (Figure 2). One
possible explanation of these results is that compound 17
targets a viral protein that is involved in multiple steps of the
viral life cycle.
Recombinant NP Abrogated the Anti-IAV Activity of
Compound 17. Since targeting multiple steps of the viral life
cycle were implicated, we speculated that IAV NP could be the
target of 17. IAV NP is a viral protein involved in multiple
stages of the IAV life cycle including intracellular trafficking of
the viral genome, viral RNA replication, and virus assembly.4
Several IAV inhibitors, such as nucleozin and naproxen, were
reported to target NP for their antiviral activity.22,23 Nucleozin
protected MDCK cells from being killed by IAV PR8 at an
EC50 of 0.71 μM (Table 1). To test whether NP was a target of
aloperine derivatives, the antiviral activity of 17 was determined
in the presence of a recombinant NP (rec-NP). Association of
the compounds with the rec-NP in culture medium is expected
to decrease the potency of the anti-IAV compounds.
Oseltamivir were used as a control in this experiment. As
expected, the rec-NP did not affect the anti-IAV activity of
oseltamivir, suggesting that the drug did not bind or interact
with the rec-NP (Figure 4). In contrast, the rec-NP significantly
abrogated the anti-VR1679 activity of 17. These results support
the notion that NP might be the target of aloperine derivatives.
In conclusion, the Sophora quinolizidine alkaloids are a class of
structurally unique natural products compared with other anti-
IAV agents. Aloperine was reported to have anti-inflammatory
and anticancer activities.24,25 It will be interesting to study if
aloperine derivatives reported here also possess anti-inflamma-
tory activity, as flu virus infection often causes inflammation of
the respiratory system. The anti-IAV mechanism of action of
the aloperine derivative is clearly different from that of
oseltamivir. Oseltamivir does not prevent the accumulation of
NP in infected MDCK cells, but 17 strongly inhibits the
expression of NP in the cells. Abrogation of the antiviral activity
of 17 by rec-NP suggests that the compound may interact with
NP. However, further studies are needed to determine if NP is
indeed the target of 17.
In summary, this study has identified a class of quinolizidine
alkaloids as new anti-IAV agents. Dihydroaloperine exhibited
the most potent anti-IAV activity among the tested
quinolizidine alkaloids. The anti-IAV potency of the
quinolizidine alkaloids could be improved by chemical
modifications on the N12 and C16 positions of the aloperine
scaffold. These compounds are effective against the PR8 virus
that is resistant to oseltamivir and amantadine. These alkaloids
have relatively low molecular mass and optimal physicochem-
ical properties (Mass = 232; Log P = 1.27 for aloperine) for
Figure 3. Compound 17 could inhibit IAV at a late stage of the viral
life cycle. MDCK cells were infected with VR1679 (MOI = 0.1) in the
presence of 17 (A) or oseltamivir (B) at various time points
postinfection (PI). Protection of MDCK cells from being killed by the
virus (% protection) was calculated with a formula detailed in the
Supporting Information. Each data point in the figure represents the
average of two independent experiments.
Figure 4. Rec-NP abrogated the anti-IAV activity of 17. Inhibition of
VR1679 infection of MDCK cells (MOI = 1) by compound 17 or
oseltamivir was determined in the presence (compound + NP) and
absence of a rec-NP at 500 μg/mL (A/Puerto Rico/8/1934, Novus
Biologicals). Percent protection of MDCK cells from being killed by
the virus was determined 2 days after infection. Each data point in the
figure represents mean ± standard deviation of three independent
experiments.
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further drug development. Thus, the quinolizidine alkaloids or




Experimental section, including materials and methods for
biological assays, synthesis, structural determination, and
spectroscopic data of synthesized compounds. This material
is available free of charge via the Internet at http://pubs.acs.org.
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